Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PROFILE: Chi-Med Lays Out Broad Strategy As Fruquintinib Advances

This article was originally published in PharmAsia News

Executive Summary

Newly NASDAQ-listed Chi-Med has completed enrollment in a Phase III trial with fruquintinib in colorectal cancer patients in China, a potentially large market for its lead drug, and is pushing ahead with US development plans for the VEGFR inhibitor. The Hong Kong-based firm also sees attractive possibilities for combination use in earlier lines of therapy and in additional indications and mature markets, its CEO says.

Advertisement

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC089551

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel